Pulmonary exacerbations · children, adolescents or adults with CF
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants at risk for apnea
It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with or at risk for apnea of prematurity
It is very uncertain whether high‐dose changes bronchopulmonary dysplasia/chronic lung disease (BPD) at 36 weeks'… compared with standard‐dose strategies (very low certainty).
3 findings from 1 review
RR 0.72 [0.47, 1.11]
3 studies · 333 participants
Very low
RR 0.68 [0.48, 0.97]
1 study · 238 participants
Low
RR 0.75 [0.6, 0.94]
5 studies · 723 participants
Moderate
Pulmonary exacerbations · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
Time to next pulmonary exacerbation · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next pulmonary exacerbation · adolescents and adults with cystic fibrosis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Time to next pulmonary exacerbation · children and adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next pulmonary exacerbation · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next pulmonary exacerbation · adolescents and adults with cystic fibrosis
Digital technology probably leads to higher time to next pulmonary exacerbation compared with usual care (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adolescents and adults with cystic fibrosis
Digital technology showed no clear difference in number of pulmonary exacerbations: number of participants… compared with usual care (moderate certainty).
1 finding from 1 review
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
Bubble showed no clear difference in bronchopulmonary dysplasia compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
Caffeine showed no clear difference in bronchopulmonary dysplasia/chronic lung disease: defined as 28 days… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.4 [0.92, 2.11]
Studies not reported
Low
c) Developmental delay more than two SDs below population mean on a standardized test of development: cognitive delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.17 [0.02, 1.37]
Studies not reported
Very low
c) Developmental delay more than two SDs below population mean on a standardized test of development: language delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.76 [0.37, 1.58]
Studies not reported
Very low
c) Developmental delay more than two SDs below population mean on a standardized test of development: motor delay № of participants: 79(1 RCT) · preterm infants
It is very uncertain whether caffeine changes c) Developmental delay more than two SDs below population mean on a… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.5 [0.13, 1.96]
Studies not reported
Very low
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).
1 finding from 1 review